Preclinical development of the green tea catechin, epigallocatechin gallate, as an HIV-1 therapy

Journal of Allergy and Clinical Immunology

Volumn 123, Issue 2, 2009, Pages 459-465

  Nance, Christina L ^a   Siwak, Edward B ^b   Shearer, William T ^a  

^a TEXAS CHILDREN S HOSPITAL   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

alternative therapy; apoptosis; cytotoxicity; EGCG; green tea; HIV; lymphocytes; p24; proliferation; subtypes

Indexed keywords

ANTIGEN P24; ANTIVIRUS AGENT; CATECHIN; CD4 ANTIGEN; EPICATECHIN GALLATE; EPIGALLOCATECHIN; EPIGALLOCATECHIN GALLATE; GLYCOPROTEIN GP 120; LIPOCORTIN 5; PYROGALLOL; RITONAVIR; THEAFLAVIN; TRYPAN BLUE; VIRUS GLYCOPROTEIN; ZIDOVUDINE;

ANTIGEN EXPRESSION; ANTIVIRAL ACTIVITY; APOPTOSIS; ARTICLE; BLOOD DONOR; BLOOD SALVAGE; CD4+ T LYMPHOCYTE; CELL GROWTH; CELL ISOLATION; CELL SURVIVAL; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DNA SYNTHESIS; DRUG EFFECT; DRUG SPECIFICITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; GROWTH INHIBITION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; INHIBITION KINETICS; MACROPHAGE; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN BINDING; TEA; VIRUS INFECTIVITY; VIRUS INHIBITION;

ANTIOXIDANTS; APOPTOSIS; CAMELLIA SINENSIS; CATECHIN; CD4-POSITIVE T-LYMPHOCYTES; CELL PROLIFERATION; CELL SURVIVAL; CELLS, CULTURED; HIV CORE PROTEIN P24; HIV INFECTIONS; HIV-1; HUMANS; MACROPHAGES;

EID: 59449105686     PISSN: 00916749     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaci.2008.12.024     Document Type: Article

References (50)

1. Kwong P., Wyatt R., Robinson J., Sweet R., Sodroski J., and Hendrickson W. Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature 393 (1998) 648-659
2. + T cells. J Biol Chem 283 (2008) 30745-30753
3. Cohen M., Hellmann N., Levy J., DeCock K., and Lange J. The spread, treatment, and prevention of HIV-1: evolution of a global pandemic. J Clin Invest 118 (2008) 1244-1254
4. Wang R., Gu Q., Wang Y., Zhang X., Yang L., Zhou J., et al. Anti-HIV-1 activities of compounds isolated from the medicinal plant Rhus chinensis. J Ethnopharmacol 117 (2008) 249-256
5. Wu J., Wang X., Yi Y., and Lee K. Anti-AIDS agents 54: a potent anti-HIV chalcone and flavonoids from genus Desmos. Bioorg Med Chem Lett 13 (2003) 1813-1815
6. Cos P., Maes L., Vanden Berghe D., Hermans N., Pieters L., and Vlietinck A. Plant substances as anti-HIV agents selected according to their putative mechanism of action. J Nat Prod 67 (2004) 284-293
7. Williamson M.P., McCormick T.G., Nance C.L., and Shearer W.T. Epigallocatechin gallate, the main polyphenol in green tea, binds to the T-cell receptor, CD4: potential for HIV-1 therapy. J Allergy Clin Immunol 118 (2006) 1369-1374
8. Havsteen B. The biochemistry and medical significance of the flavonoids. Pharmacol Ther 96 (2002) 67-202
9. Nair M., Kandaswami C., Mahajan S., Nair H., Chawda R., Shanahan T., et al. Grape seed extract proanthocyanidins downregulate HIV-1 entry coreceptors, CCR2b, CCR3 and CCR5 gene expression by normal peripheral blood mononuclear cells. Biol Res 35 (2002) 421-431
10. Leung L., Su Y., Chen R., Zhang Z., Huang Y., and Chen Z. Theaflavins in black tera and catechins in green tea are equally effective antioxidants. J Nutr 131 (2001) 2248-2251
11. Kanadzu M., Lu Y., and Morimoto K. Dual function of (-)-epigallocatechin gallate (EGCG) in healthy human lymphocytes. Cancer Lett 241 (2006) 250-255
12. Liu S., Lu H., Zhao Q., He Y., Niu J., Debnath A.K., et al. Theaflavin derivatives in black tea and catechin derivatives in green tea inhibit HIV-1 entry by targeting gp41. Biochim Biophys Acta 1723 (2005) 270-281
13. Lee M., Wang Z., Li H., Chen L., Sun Y., Gobbo S., et al. Analysis of plasma and urinary tea polyphenols in human subjects. Cancer Epidemiol Biomarkers Prev 4 (1995) 393-399
14. Lambert J., and Yang C. Cancer chemopreventive activity and bioavailability of tea and tea polyphenols. Mutat Res 523-524 (2003) 201-208
15. Dona M., Dell'Aica I., Calabrese F., Benelli R., Morini M., Albini A., et al. Neutrophil restraint by green tea: inhibition of inflammation, associated angiogenesis, and pulmonary fibrosis. J Immunol 170 (2003) 4335-4341
16. Takano K., Nakaima K., Nitta M., Shibata F., and Nakagawa H. Inhibitory effect of (-)-epigallocatechin 3-gallate, a polyphenol of green tea, on neutrophil chemotaxis in vitro and in vivo. J Agric Food Chem 52 (2004) 4571-4576
17. Hofbauer R., Frass M., Gmeiner B., Handler S., Speiser W., and Kapiotis S. The green tea extract epigallocatechin gallate is able to reduce neutrophil transmigration through monolayers of endothelial cells. Wien Klin Wochenschr 111 (1999) 278-282
18. Yamashita K., Suzuki Y., Matsui T., Yoshimaru T., Yamaki M., Suzuki-Karasaki M., et al. Epigallocatechin gallate inhibits histamine relase from rat basophilic leukemia (RBL-2H3) cells: role of tyrosine phosphorylation pathway. Biochem Biophys Res Commun 274 (2000) 603-608
19. Suzuki M., Yoshino K., Maeda-Yamamoto M., Miyase T., and Sano M. Inhibitory effects of tea catechins and O-methylated derivatives of (-)-epigallocatechin-3-O-gallate on mouse type IV allergy. J Agric Food Chem 48 (2000) 5649-5653
20. Xu J., Wang J., Deng F., Hu Z., and Wang H. Green tea extract and its major component epigallocatechin gallate inhibits hepatitis B virus in vitro. Antiviral Res 78 (2008) 242-249
21. Song J.M., Lee K.H., and Seong B.L. Antiviral effect of catechins in green tea on influenza virus. Antiviral Res 68 (2005) 66-74
22. Lambert J.D., and Yang C.S. Mechanisms of cancer prevention by tea constituents. J Nutr 133 (2003) 3262S-3267S
23. Fassina G., Buffa A., Benelli R., Varnier O.E., Noonan D.M., and Albini A. Polyphenolic antioxidant (-)-epigallocatechin-3-gallate from green tea as a candidate anti-HIV agent. AIDS 16 (2002) 939-941
24. Kawai K., Tsuno N.H., Kitayama J., Okaji Y., Yazawa K., Asakage M., et al. Epigallocatechin gallate, the main component of tea polyphenol, binds to CD4 and interferes with gp120 binding. J Allergy Clin Immunol 112 (2003) 951-957
25. Yamaguchi K., Honda M., Ikigai H., Hara Y., and Shimamura T. Inhibitory effects of (-)-epigallocatechin gallate on the life cycle of human immunodeficiency virus type 1 (HIV-1). Antiviral Res 53 (2002) 19-34
26. Patke C., and Shearer W. gp120- and TNF-alpha-induced modulation of human B cell function: proliferation, cyclic AMP generation, Ig production, and B-cell receptor expression. J Allergy Clin Immunol 105 (2000) 975-982
27. Asres K., Seyoum A., Veersham C., Bucar F., and Gibbons S. Naturally derived anti-HIV agents. Phytother Res 19 (2005) 557-581
28. De Clercq E. Current lead natural products for the chemotherapy of human immunodeficiency virus (HIV) infection. Med Res Rev 20 (2000) 323-349
29. Zaveri N.T. Synthesis of a 3,4,5-trimethoxybenzoyl ester analogue of epigallocatechin-3-gallate (EGCG): a potential route to the natural product green tea catechin, EGCG. Org Lett 3 (2001) 843-846
30. Baeten J., Chohan B., Lavreys L., Chohan V., McClelland R., Certain L., et al. HIV-1 subtype D infection is associated with faster disease progression than subtype A in spite of similar plasma HIV-1 loads. J Infect Dis 195 (2007) 1177-1180
31. McCutchan F. Understanding the genetic diversity of HIV-1. AIDS 14 suppl 3 (2000) S31-S44
32. UNAIDS, WHO UNAIDS/WHO epidemiological fact sheets on HIV/AIDS and sexually transmitted diseases, 2009 update Available at: http://www.who.int/hiv/pub/epidemiology/pubfacts/en/. 2009.
33. Butler I., Pandrea I., Marx P., and Apetrei C. HIV genetic diversity: biological and public health consequences. Curr HIV Res 5 (2007) 23-45
34. Babich H., Krupka M., Nissim H., and Zuckerbraun H. Differential in vitro cytotoxicity of (-)-epicatechin gallate (ECG) to cancer and normal cells from the human oral cavity. Toxicol in Vitro 19 (2005) 231-242
35. Ahmad N., Gupta S., and Mukhtar H. Green tea polyphenol epigallocatechin-3-gallate differentially modulates nuclear factor κB in cancer cells versus normal cells. Arch Biochem Biophys 376 (2000) 338-346
36. Hu Z., Toda M., Okubo S., Hara Y., and Shimamura T. Mitogenic activity of (-) epigallocatechin gallate on B-cells and investigation of its structure-function relationship. Int J Immunopharmacol 14 (1992) 1399-1407
37. Shammas M., Neri P., Koley H., Batchu R., Bertheau R., Munshi V., et al. Specific killing of multiple myeloma cells by (-)-epigallocatechin-3-gallate extracted from green tea: biological activity and therapeutic implications. Blood 108 (2006) 2804-2810
38. Landis-Piwowar K., Kuhn D., Wan S., Chen D., Chan T., and Dou Q. Evaluation of proteasome-inhibitory and apoptosis-inducing potencies of novel (-)-EGCG analogs and their prodrugs. Int J Mol Med 15 (2005) 735-742
39. Roy A., Baliga M., and Katiyar S. Epigallocatechin-3-gallate induces apoptosis in estrogen receptor-negative human breast carcinoma cells via modulation in protein expression of p53 and Bax and caspase-3 activation. Mol Cancer Ther 4 (2005) 81-90
40. Khan N., Afaq F., Saleem M., Ahmad N., and Mukhtar H. Targeting multiple signaling pathways by green tea polyphenol (-)-epigallocatechin-3-gallate. Cancer Res 66 (2006) 2500-2505
41. Kawai K., Tsuno N.H., Kitayama J., Okaji Y., Yazawa K., Asakage M., et al. Epigallocatechin gallate induces apoptosis of monocytes. J Allergy Clin Immunol 115 (2005) 186-191
42. Aktas O., Prozorovski T., Smorodchenko A., Savaskan N., Lauster R., Kloetzel P., et al. Green tea Epigallocatechin-3-gallate mediates T cellular NF-kB inhibition and exerts neuroprotection in autoimmune encephalomyelitis. J Immunology 173 (2004) 5794-5800
43. Noda C., He J., Takano T., Tanaka C., Kondo T., Tohyama K., et al. Induction of apoptosis by epigallocatechin-3-gallate in human lymphoblastoid B cells. Biochem Biophys Res Commun 362 (2007) 951-957
44. Chow H., Cai Y., Alberts D., Hakim I., Dorrl R., Shahi F., et al. Phase I pharmacokinetic study of tea polyphenols following single-dose administration of epigallocatechin gallate and polyphenon E. Cancer Epidemiol Biomarkers Prev 10 (2001) 53-58
45. Chow H.H., Cai Y., Hakim I.A., Crowell J.A., Shahi F., Brooks C.A., et al. Pharmacokinetics and safety of green tea polyphenols after multiple-dose administration of epigallocatechin gallate and polyphenon E in healthy individuals. Clin Cancer Res 9 (2003) 3312-3319
46. Sleasman J.W., and Goodenow M.M. HIV-1 infection. J Allergy Clin Immunol 111 (2003) S582-S592
47. Chow H.H., Hakim I., Vining D.R., Crowell J.A., Ranger-Moore J., Chew W.M., et al. Effects of dosing condition on the oral bioavailability of green tea catechins after single-dose administration of polyphenon E in healthy individuals. Clin Cancer Res 11 (2005) 4627-4633
48. Ullman U., Haller J., Decourt J., Girault N., Girault J., Richard-Caudron A., et al. A single ascending dose study of epigallocatechin gallate in healthy volunteers. J Int Med Res 31 (2003) 88-101
49. Bettuzzi S., Brausi M., Rizzi F., Castagnetti G., Peracchia G., and Corti A. Chemoprevention of human prostate cancer by oral administration of green tea catechins in volunteers with high-grade prostate intraepithelial neoplasia: a preliminary report from a one-year proof-of-principle study. Cancer Res 66 (2006) 1234-1240
50. Donovan J., Chavin K., DeVane C., Taylor R., Wang J., Ruan Y., et al. Green tea (Camellia sinensis) extract does not alter cytochrome P450 3A4 or 2D6 activity in healthy volunteers. Drug Metab Dispos 32 (2004) 906-908